**Question:** Platelet aggregation is caused by all, except

A. Platelet-activating factor (PAF)
B. Serotonin
C. ADP
D. Thromboxane A2

**Core Concept:** Platelet aggregation is a crucial process in hemostasis, which involves the temporary formation of a blood clot at sites of vascular injury to prevent bleeding. This process is triggered by various agonists, including ADP, thromboxane A2, and serotonin. Platelet-activating factor (PAF), on the other hand, is an anaphylatoxin that plays a role in inflammation, but it does not directly induce platelet aggregation.

**Why the Correct Answer is Right:** Option A, PAF, is the correct answer because it is primarily involved in mediating inflammation and is not a direct platelet aggregator. In contrast, ADP, thromboxane A2, and serotonin are known to stimulate platelet aggregation through specific receptors and pathways.

**Why Each Wrong Option is Incorrect:**

Option B, serotonin, is incorrect because it is a potent platelet aggregator acting on serotonin receptors, specifically 5-hydroxytryptamine receptors. Serotonin released from platelets and other sources stimulates platelet aggregation through the release reaction.

Option C, ADP, is incorrect because it is a potent platelet aggregator that binds to adenosine receptors, specifically P2Y1 and P2Y12. ADP release from activated platelets initiates a cascade of events leading to platelet aggregation.

Option D, thromboxane A2, is incorrect because it is a potent platelet aggregator acting on thromboxane A2 receptors, specifically TP receptors. Thromboxane A2 is a prostanoid formed from arachidonic acid via the action of cyclooxygenase enzymes. It plays a critical role in platelet aggregation and vasoconstriction.

**Clinical Pearl:** Understanding the role of these agonists in platelet aggregation is crucial for understanding therapeutic strategies targeting these molecules, such as aspirin (acetylsalicylic acid), which irreversibly inhibits cyclooxygenase-1, thereby blocking the formation of thromboxane A2 and reducing platelet aggregation.

**Core Concept:** Platelets are small, anucleate cell fragments derived from megakaryocytes, which play a vital role in hemostasis and thrombosis. Platelet activation and aggregation occur in response to various agonists, including ADP, thromboxane A2, and serotonin. Platelet-activating factor (PAF) is an inflammatory mediator involved in the process of platelet aggregation but is not directly responsible for platelet activation.

**Why Each Wrong Option is Incorrect:**

Option A, PAF, is incorrect because it is primarily involved in the inflammatory response and increases vascular permeability but does not directly activate or aggregate platelets. PAF works indirectly by promoting the release of ADP and thromboxane A2, which are direct platelet activators.

**Clinical Pearl:** The understanding of these agonists in platelet aggregation is fundamental for selecting appropriate antiplatelet therapy, such as P2Y12 inhibitors (e.g